Managing paediatric gastroenteritis in primary care: is there a role for ondansetron?
Abstract
Despite the reduction in hospital admissions 1 and deaths 2 due to the rotavirus vaccine, acute gastroenteritis remains a major cause of morbidity and healthcare service use worldwide.While typically a self-limited illness, the mainstay of therapy is oral rehydration therapy (ORT) to prevent the need for intravenous fluids and hospital admission due to severe dehyration.3 In 2006, a randomised controlled trial (RCT) by Freedman et al showed that a single dose of ondansetron in the emergency department (ED), compared with placebo, reduces the likelihood of vomiting and the need for intravenous rehydration.4 This seminal trial changed the standard of ED care for children with gastroenteritis but evidence was lacking for its use in primary care. LATEST RESEARCH ON ONDANSETRON IN THE BJGPIn this issue of the BJGP, Bonvanie et al report an important pragmatic RCT evaluating the addition of oral ondansetron to usual care in children presenting with acute gastroenteritis in the out-of-hours primary care setting.5 The trial was conducted between 2015 and 2018 in three Dutch centres for out-of-hours care, and included children aged between 6 months and 6 years diagnosed with acute gastroenteritis -defined as ≥4 episodes of vomiting in the 24 hours before presenting, including one episode within 4 hours of presentation.Usual care for children included the provision of ORT, either 10 ml/kg or 15 ml/kg for 4 hours based on hydration status along with administration instructions.Children…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.